<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03452033</url>
  </required_header>
  <id_info>
    <org_study_id>ALY337-201</org_study_id>
    <nct_id>NCT03452033</nct_id>
  </id_info>
  <brief_title>H-1337 Ophthalmic Solution Phase 1/2</brief_title>
  <official_title>A Phase 1/2a Randomized, Double-masked, Placebo Controlled, Dose-ranging Study of the Safety and Efficacy of H-1337 in Subjects With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allysta Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allysta Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will evaluate the safety, tolerability, and preliminary efficacy of three&#xD;
      concentrations of H-1337 and vehicle administered twice daily in a parallel group,&#xD;
      double-masked design for 28 days of dosing in patients with elevated intraocular pressure&#xD;
      (IOP).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study ALY337-201 will be a double-masked, randomized, placebo-controlled, dose-response study&#xD;
      assessing the safety and ocular hypotensive efficacy of H-1337 ophthalmic solution in&#xD;
      subjects with ocular hypertension (OHT) or open angle glaucoma.&#xD;
&#xD;
      During screening, subjects who meet the preliminary inclusion/exclusion criteria will&#xD;
      discontinue use of their ocular hypotensive therapy during the washout period. The washout&#xD;
      duration will be dependent on the subject's pre-study ocular hypotensive therapy. Starting on&#xD;
      Day 0, those who continue to meet the inclusions/exclusion criteria and the diurnal IOP&#xD;
      criteria will be randomized into one of the treatments arms and dosing will be initiated,&#xD;
      continuing for 28 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 15, 2018</start_date>
  <completion_date type="Actual">August 15, 2018</completion_date>
  <primary_completion_date type="Actual">August 15, 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double-masked, parallel</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double-masked containers</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Intraocular Pressure (IOP)</measure>
    <time_frame>Baseline and 28 days</time_frame>
    <description>Mean change in IOP from baseline on Day 28 (Time 0 + 4h)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>28 days</time_frame>
    <description>Number of participants with treatment-emergent adverse events</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">87</enrollment>
  <condition>Glaucoma, Open-Angle</condition>
  <arm_group>
    <arm_group_label>H-1337 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>H-1337 Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>H-1337 [1]</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>H-1337 [1]</description>
  </arm_group>
  <arm_group>
    <arm_group_label>H-1337 [2]</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>H-1337 [2]</description>
  </arm_group>
  <arm_group>
    <arm_group_label>H-1337 [3]</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>H-1337 [3]</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>H-1337 Placebo</intervention_name>
    <description>H-1337 Placebo Vehicle</description>
    <arm_group_label>H-1337 Placebo</arm_group_label>
    <other_name>Vehicle</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>H-1337 [1]</intervention_name>
    <description>H-1337 Ophthalmic Solution Concentration 1</description>
    <arm_group_label>H-1337 [1]</arm_group_label>
    <other_name>H-1337 conc 1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>H-1337 [2]</intervention_name>
    <description>H-1337 Ophthalmic Solution Concentration 2</description>
    <arm_group_label>H-1337 [2]</arm_group_label>
    <other_name>H-1337 conc 2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>H-1337 [3]</intervention_name>
    <description>H-1337 Ophthalmic Solution Concentration 3</description>
    <arm_group_label>H-1337 [3]</arm_group_label>
    <other_name>H-1337 conc 3</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 18 years of age or older.&#xD;
&#xD;
          2. Diagnosis of bilateral primary open angle glaucoma or ocular hypertension.&#xD;
&#xD;
          3. One qualifying IOP criteria after washout:&#xD;
&#xD;
             • Baseline (Day 0) at T0 (T0 = 8 am ± 30 min) IOP ≥ 23 mmHg in the study eye.&#xD;
&#xD;
          4. IOP criteria after washout ≤ 32 mmHg oculus uterque (OU) at all time points.&#xD;
&#xD;
          5. Best-corrected visual acuity (BCVA) in both eyes of 20/200 or better on Snellen,&#xD;
             equivalent to + 1.0 log Mar.&#xD;
&#xD;
          6. Able and willing to sign informed consent, follow study instructions and complete all&#xD;
             study visits.&#xD;
&#xD;
          7. As applicable, must be willing to discontinue the use of all ocular hypotensive&#xD;
             medication(s) in both eyes prior to receiving the study medication and for the entire&#xD;
             course of the study.&#xD;
&#xD;
          8. Able to self-administer or have a caretaker administer study eye drops.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Ophthalmic:&#xD;
&#xD;
        Exclude subjects with:&#xD;
&#xD;
          1. Closed or very narrow angles (Grade 0-1) (see Section 5, gonioscopy) or those the&#xD;
             investigator judges as occludable and/or with evidence of peripheral anterior&#xD;
             synechiae (PAS) ≥ 180 degrees by gonioscopy within 6 months prior to Screening Visit&#xD;
             in either eye. (Patent laser iridotomy with Grade 1-2 angles is acceptable in either&#xD;
             eye, providing the PAS criteria are still met).&#xD;
&#xD;
          2. Previous glaucoma intraocular surgery in either eye. Prior laser trabeculoplasty (ALT&#xD;
             or SLT) in either eye is allowed if performed more than 6 months prior to Screening&#xD;
             Visit.&#xD;
&#xD;
          3. Any non-glaucoma intraocular surgery within 3 months prior to Screening Visit in&#xD;
             either eye.&#xD;
&#xD;
          4. Intraocular laser surgery such as laser capsulotomy, laser iridotomy, and/or retinal&#xD;
             laser within 1 month prior to Screening Visit in either eye.&#xD;
&#xD;
          5. Significant media opacity in either eye that would impede adequate posterior segment&#xD;
             examination.&#xD;
&#xD;
          6. Contraindications to pupil dilation in either eye.&#xD;
&#xD;
          7. Other forms of glaucoma such as primary congenital, juvenile onset, chronic angle&#xD;
             closure, and secondary glaucoma of any type including steroid-induced,&#xD;
             inflammation-induced, or exfoliation glaucoma in either eye. Pigment dispersion&#xD;
             syndrome/glaucoma is permitted in either eye.&#xD;
&#xD;
          8. Clinically significant corneal dystrophy, epithelial or endothelial disease, corneal&#xD;
             irregularities or scarring that, in the investigator's judgment, would impede an&#xD;
             accurate measurement of IOP or visualization of intraocular anatomy in the study eye.&#xD;
&#xD;
          9. History of refractive surgery in either eye (i.e., radial keratotomy, photorefractive&#xD;
             keratectomy, LASIK).&#xD;
&#xD;
         10. History of corneal cross-linking procedure in either eye.&#xD;
&#xD;
         11. Unwillingness to be contact lens free during study participation.&#xD;
&#xD;
         12. Any history of uveitis, keratitis, or scleritis in either eye.&#xD;
&#xD;
         13. Any history of penetrating ocular trauma in either eye.&#xD;
&#xD;
         14. History within 3 months prior to Screening Visit of clinically significant moderate or&#xD;
             severe chronic or active blepharitis, ocular dermatitis, or recent ocular&#xD;
             conjunctivitis and/or ocular inflammation in either eye. Mild blepharitis, hyperemia&#xD;
             (due to prostaglandin use) and/or blepharitis, and/or mild inactive seasonal allergic&#xD;
             conjunctivitis and non-infective dermatitis are acceptable.&#xD;
&#xD;
         15. Corneal thickness &lt; 480 or &gt; 620 µm in the study eye. Pachymetry measurement within 6&#xD;
             months prior to Screening Visit is acceptable.&#xD;
&#xD;
         16. Advanced or severe glaucoma with progressive visual field loss and/or optic nerve&#xD;
             changes in either eye that, in the investigator's best judgment, prevent safe&#xD;
             withdrawal from treatment for the time periods required in this protocol.&#xD;
&#xD;
         17. Progressive retinal (including, but not limited to worsening dry age-related macular&#xD;
             degeneration (AMD), presence of active wet AMD, or unstable diabetic retinopathy) or&#xD;
             optic nerve disease in either eye from any cause other than glaucoma.&#xD;
&#xD;
         18. Any prior intravitreal steroid injection in either eye.&#xD;
&#xD;
         19. Sub-tenon's, sub-conjunctival or periocular steroid injections within the 6 months&#xD;
             prior to Screening Visit in either eye.&#xD;
&#xD;
         20. Any use of ocular topical corticosteroids in either eye within 7 days, or chronic (as&#xD;
             determined by the investigator) topical steroids within 28 days prior to Baseline and&#xD;
             ensuing trial participation.&#xD;
&#xD;
         21. Known hypersensitivity to any component of the H-1337 formulation, including&#xD;
             benzalkonium chloride, or to topical anesthetics or diagnostic drops used during the&#xD;
             study.&#xD;
&#xD;
         22. Any ocular, condition that, in the investigator's judgment, could prevent the subject&#xD;
             from safe participation the study.&#xD;
&#xD;
         23. Planned ocular surgery or intraocular injection procedure in either eye during study&#xD;
             participation.&#xD;
&#xD;
             General/Systemic:&#xD;
&#xD;
         24. Participation in a clinical study with use of any investigational drug or treatment&#xD;
             within 30 days prior to Baseline (Day 0).&#xD;
&#xD;
         25. Clinically significant abnormalities in: laboratory tests, physical examination, vital&#xD;
             signs and/or ECG at Screening Visit. If in the investigator's judgment a subject with&#xD;
             clinically significant abnormalities is appropriate for enrollment in the study, a&#xD;
             discussion between the investigator and the Medical Monitor must occur and be&#xD;
             documented prior to enrollment of this subject in the study.&#xD;
&#xD;
         26. Clinically significant systemic, psychiatric or psychological disease (for example,&#xD;
             renal, hepatic, uncontrolled diabetes, uncontrolled blood pressure, autoimmune&#xD;
             disorders, psychiatric disorders, endocrine disorders, or any other disorders) or&#xD;
             dependency which, in the investigator's judgment, would be unsafe and interfere with&#xD;
             interpretation of the study results or the subject's ability to comply with the study&#xD;
             requirements.&#xD;
&#xD;
         27. Anticipated changes or initiation of medications which might affect IOP and/or&#xD;
             systemic blood pressure within 7 days prior to Baseline/Day 0 (e.g., oral&#xD;
             anti-hypertensives such as sympathomimetic agents, beta-adrenergic blocking agents,&#xD;
             alpha agonists, alpha adrenergic blocking agents, calcium channel blockers,&#xD;
             angiotensin converting enzyme inhibitors; [diuretics are allowed]), and 2 months prior&#xD;
             to Baseline/Day 0 for corticosteroids (i.e., oral, nasal, topical [dermal, mucosal],&#xD;
             and/or inhaled corticosteroids). If there are no further anticipated changes in&#xD;
             medications that could affect IOP and/or systemic blood pressure, then once the&#xD;
             subject is stable on their new dose of medication for the required time period, the&#xD;
             subject may complete the Baseline Visit, assuming that all other screening&#xD;
             requirements are met. Medications used on an adjustable or sliding scale based on&#xD;
             testing results are allowed.&#xD;
&#xD;
         28. Known history of Hepatitis B + C, HIV+, or AIDS and/or inadequate venous access.&#xD;
&#xD;
         29. Women of childbearing potential who are pregnant, nursing, planning a pregnancy, or&#xD;
             not using a medically acceptable form of birth control. An adult woman is considered&#xD;
             to be of childbearing potential unless she is one year post-menopausal or three months&#xD;
             post-surgical sterilization. All females of childbearing potential must have a&#xD;
             negative serum pregnancy test result at Screening Visit and a negative urine and serum&#xD;
             pregnancy test at Baseline (Day 0) prior to randomization in the study and must not&#xD;
             intend to become pregnant during the study.&#xD;
&#xD;
         30. History of drug or alcohol abuse within the last 5 years.&#xD;
&#xD;
         31. Related to site study staff and/or site employees.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>PRN</name>
      <address>
        <city>Goose Creek</city>
        <state>South Carolina</state>
        <zip>29445</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>February 26, 2018</study_first_submitted>
  <study_first_submitted_qc>February 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 2, 2018</study_first_posted>
  <results_first_submitted>June 21, 2021</results_first_submitted>
  <results_first_submitted_qc>July 12, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 2, 2021</results_first_posted>
  <disposition_first_submitted>July 16, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>July 12, 2021</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">August 2, 2021</disposition_first_posted>
  <last_update_submitted>July 12, 2021</last_update_submitted>
  <last_update_submitted_qc>July 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>glaucoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No plan at current.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 8, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/33/NCT03452033/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 6, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/33/NCT03452033/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 87 subjects were enrolled and randomized across 6 investigational sites in the United States.</recruitment_details>
      <pre_assignment_details>During the screening phase (Screening and Baseline Visits), subjects washed out any current ocular hypotensive therapy according to the below schedule:&#xD;
Muscarinic agonists (eg, pilocarpine) and oral or topical carbonic anhydrase inhibitor (CAIs): ≥5 days Alpha adrenoceptor agonists: ≥5 weeks Beta-adrenoceptor antagonists: ≥6 weeks Prostaglandin analogues and combination drugs (use longest wash-out period of individual components): ≥6 weeks</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>H-1337 0.06%</title>
          <description>H-1337 Ophthalmic Solution Concentration 0.06%</description>
        </group>
        <group group_id="P2">
          <title>H-1337 0.2%</title>
          <description>H-1337 Ophthalmic Solution Concentration 0.2%</description>
        </group>
        <group group_id="P3">
          <title>H-1337 0.6%</title>
          <description>H-1337 Ophthalmic Solution Concentration 0.6%</description>
        </group>
        <group group_id="P4">
          <title>Vehicle</title>
          <description>Vehicle (contains all components of the active formulation with the exception of H-1337)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="22"/>
                <participants group_id="P4" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="22"/>
                <participants group_id="P4" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>H-1337 0.06%</title>
          <description>H-1337 Ophthalmic Solution Concentration 0.06%</description>
        </group>
        <group group_id="B2">
          <title>H-1337 0.2%</title>
          <description>H-1337 Ophthalmic Solution Concentration 0.2%</description>
        </group>
        <group group_id="B3">
          <title>H-1337 0.6%</title>
          <description>H-1337 Ophthalmic Solution Concentration 0.6%</description>
        </group>
        <group group_id="B4">
          <title>Vehicle</title>
          <description>Vehicle (contains all components of the active formulation with the exception of H-1337)</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
            <count group_id="B2" value="22"/>
            <count group_id="B3" value="22"/>
            <count group_id="B4" value="22"/>
            <count group_id="B5" value="87"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.1" spread="13.58"/>
                    <measurement group_id="B2" value="64.1" spread="10.02"/>
                    <measurement group_id="B3" value="67.4" spread="11.72"/>
                    <measurement group_id="B4" value="65.0" spread="14.44"/>
                    <measurement group_id="B5" value="64.5" spread="12.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="52"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="78"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="77"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="22"/>
                    <measurement group_id="B5" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Intraocular pressure</title>
          <description>measured in mmHg&#xD;
Randomization stratum for IOP (≤26 mmHg and &gt;26 mmHg)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>≤26 mmHg</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="58"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;26 mmHg</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Intraocular Pressure (IOP)</title>
        <description>Mean change in IOP from baseline on Day 28 (Time 0 + 4h)</description>
        <time_frame>Baseline and 28 days</time_frame>
        <population>mmHg in the study eye</population>
        <group_list>
          <group group_id="O1">
            <title>H-1337 0.06%</title>
            <description>H-1337 Ophthalmic Solution 0.06%</description>
          </group>
          <group group_id="O2">
            <title>H-1337 0.2%</title>
            <description>H-1337 Ophthalmic Solution 0.2%</description>
          </group>
          <group group_id="O3">
            <title>H-1337 0.6%</title>
            <description>H-1337 Ophthalmic Solution 0.6%</description>
          </group>
          <group group_id="O4">
            <title>Vehicle</title>
            <description>Vehicle (contains all components of the active formulation with the exception of H-1337)</description>
          </group>
        </group_list>
        <measure>
          <title>Intraocular Pressure (IOP)</title>
          <description>Mean change in IOP from baseline on Day 28 (Time 0 + 4h)</description>
          <population>mmHg in the study eye</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>study eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>study eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.40" spread="3.734"/>
                    <measurement group_id="O2" value="-5.11" spread="3.284"/>
                    <measurement group_id="O3" value="-5.20" spread="3.801"/>
                    <measurement group_id="O4" value="0.09" spread="2.562"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events</title>
        <description>Number of participants with treatment-emergent adverse events</description>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>H-1337 0.06%</title>
            <description>H-1337 Ophthalmic Solution Concentration 0.06%</description>
          </group>
          <group group_id="O2">
            <title>H-1337 0.2%</title>
            <description>H-1337 Ophthalmic Solution Concentration 0.2%</description>
          </group>
          <group group_id="O3">
            <title>H-1337 0.6%</title>
            <description>H-1337 Ophthalmic Solution Concentration 0.6%</description>
          </group>
          <group group_id="O4">
            <title>Vehicle</title>
            <description>Vehicle (contains all components of the active formulation with the exception of H-1337)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events</title>
          <description>Number of participants with treatment-emergent adverse events</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>28 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>H-1337 0.06%</title>
          <description>H-1337 Ophthalmic Solution Concentration 0.06%</description>
        </group>
        <group group_id="E2">
          <title>H-1337 0.2%</title>
          <description>H-1337 Ophthalmic Solution Concentration 0.2%</description>
        </group>
        <group group_id="E3">
          <title>H-1337 0.6%</title>
          <description>H-1337 Ophthalmic Solution Concentration 0.6%</description>
        </group>
        <group group_id="E4">
          <title>Vehicle</title>
          <description>Vehicle (contains all components of the active formulation with the exception of H-1337)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye disorders</sub_title>
                <counts group_id="E1" events="21" subjects_affected="5" subjects_at_risk="21"/>
                <counts group_id="E2" events="22" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E3" events="22" subjects_affected="5" subjects_at_risk="22"/>
                <counts group_id="E4" events="22" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General disorders and administration site conditiions</sub_title>
                <counts group_id="E1" events="21" subjects_affected="6" subjects_at_risk="21"/>
                <counts group_id="E2" events="22" subjects_affected="8" subjects_at_risk="22"/>
                <counts group_id="E3" events="22" subjects_affected="13" subjects_at_risk="22"/>
                <counts group_id="E4" events="22" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Shigenobu Nakazora</name_or_title>
      <organization>D. Western Therapeutics Institute</organization>
      <phone>+81-52-218-8785</phone>
      <email>shinakazora@dwti.co.jp</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

